Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

Overview:

Acute lymphoblastic leukemia (ALL) remains a challenging and aggressive malignancy, with adult patients continuing to experience poor outcomes despite progress in pediatric treatment strategies. Although advances in T-cell–based therapies—such as CAR T-cell therapies and bispecific antibodies—offer promising new options, they also introduce complexity in patient selection, sequencing, and toxicity management. With emerging data from the 2025 ASH Annual Meeting shifting treatment paradigms, clinicians still face gaps in applying new evidence and navigating the unique adverse events associated with these therapies.

To address these needs, this initiative will feature a PER® Oncology Town Hall, a live CME-certified webcast designed to quickly deliver key ASH 2025 updates and provide expert guidance on integrating T-cell therapies into practice. The program recreates the experience of a major conference session and includes faculty-led discussions that translate new findings into real-world clinical decision-making.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Evaluate recent clinical trial data on approved and emerging therapeutic strategies for ALL, with a focus on advances in bispecific antibodies and CAR-T cell therapies
• Interpret the latest guidelines and evidence for biomarker-driven strategies to stratify risk and guide the use of bispecific and CAR-T cell therapies in patients with ALL
• Describe best practices for mitigating and managing treatment-related adverse events in patients with ALL

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medical Oncologists (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.